Tacrolimus Inhalation Aerosol
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Tacrolimus Inhalation Aerosol
Tacrolimus Inhalation Aerosol is a phase 2 stage product being developed by Astellas Pharma for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00116103. Target conditions include Asthma.
What happened to similar drugs?
20 of 20 similar drugs in Asthma were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00116103 | Phase 2 | Completed |
Competing Products
20 competing products in Asthma